Pathologists’ diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study

The goal of a medical diagnosis is to identify and assign natural phenomena to the correct diagnostic classification with both accuracy and precision. However, inadequate development and inconsistent use of disease labels and classification schemes by clinicians can lead to patient harm.23 While physicians may observe similar features on a biopsy sample slide or radiograph or on a patient’s physical examination, their diagnosis reflects individual perspectives in the processing, assigning of importance, and categorising of medical information. As diagnostic criteria increase in their subjectivity, diagnoses between physicians become increasingly discordant.

bmj.com


Patients in Treatment for Melanoma Require Close Monitoring

Jennifer A. Stein, MD, PhDJennifer A. Stein, MD, PhD

Being on treatment for melanoma still requires physicians to examine their patients for new primary melanomas, which are likely to occur especially in patients on a BRAF inhibitor, according to Jennifer A. Stein, MD, PhD.

Moreover, the skin-related adverse events (AEs) patients experience, regardless of their treatment with a checkpoint inhibitor or with a targeted therapy, also need to be closely monitored and, if necessary, properly managed with topical steroids or antihistamines.

In a recent interview with Oncology Nursing News, Stein, an associate professor of dermatology at New York University School of Medicine in New York, discusses the skin-related AEs for patients on treatment for melanoma, as well as the importance of identifying new primary melanomas.


Melanoma awareness Ireland are running A CAMPAIGN TO TRY TO GET SUNBEDS BANNED HERE IN IRELAND.

We believe Ireland should follow the lead of Australia and ban sunbed use.

Research has shown that people who have EVER used a sunbed are 20% more likely to develop melanoma in later life, and with the projected increase in incidence rates of melanoma published in 2014 by the NCRI who have predicted an increase of 175% in Women and 327% in men by 2040 (very frightening statistics) It’s time to try to do something.

Please sign the petition by following this link.

Sign Petition


Learning from PD-1 Resistance: New Combination Strategies

Only a minority of cancer patients respond to anti PD-1 immunotherapy. A recent study demonstrates that PD-1 therapy-resistant melanoma patients present distinct signatures of upregulated genes involved in immunosuppression, angiogenesis, monocyte and macrophage chemotaxis, extracellular matrix remodeling, and epithelial–mesenchymal transition (EMT). Combination targeting of these pathways with PD-1 may help overcome PD-1 resistance, thus producing effective antitumor immunity.

Cell.com


Sun safety in cars
Family-CarFor most people, car safety means seat belts and airbags. But there’s another important way to stay out of harm’s way on the road, and that’s by protecting your skin from the sun.A study in the Journal of the American Academy of Dermatology revealed that nearly 53 percent of skin cancers in the US occur on the left, or drivers’ side of the body. If you’re one of the approximately 208 million licensed drivers in the US, take heed: “The increase in left-sided skin cancers may be from the UV (ultraviolet) exposure we get when driving a car,” said Susan T. Butler, MD, coauthor of the study.skincancer.org


Indoximod plus pembrolizumab prompts response in advanced melanoma
 April 6, 2017

The addition of investigational immunotherapy indoximod to pembrolizumab conferred superior response rates in patients with advanced melanoma, according to interim results of a phase 2 clinical trial presented at the American Association for Cancer Research Annual Meeting.

Healio.com


 

Key Statistics for Melanoma Skin Cancer

Cancer of the skin is by far the most common of all cancers. Melanoma accounts for only about 1% of skin cancers but causes a large majority of skin cancer deaths.

How common is melanoma?

The American Cancer Society’s estimates for melanoma in the United States for 2017 are:

  • About 87,110 new melanomas will be diagnosed (about 52,170 in men and 34,940 in women).
  • About 9,730 people are expected to die of melanoma (about 6,380 men and 3,350 women).

The rates of melanoma have been rising for the last 30 years.

cancer.org


Petition
The approval of new treatments for All Melanoma Patients living in Ireland

Sign Petition


More foreign holidays will mean more skin cancer, scientists predict

A 78% increase in non-melanoma skin cancer may see the cost to the NHS of treating the disease rise to £465m a year by 2025

Beach with sunbathers
More affordable foreign holidays and the increased use of sunbeds have both had an effect on the frequency of skin cancer cases. Photograph: Alamy

The number of Britons developing the two most common forms of skin cancer will increase as a direct result of people getting tans on foreign holidays and in salons, experts are warning.

The number of people diagnosed with non-melanoma skin cancer (NMSC) will rise from the 213,217 seen in 2010 to 380,002 cases a year by 2025, according to a study in a medical journal.

That predicted 78% increase could also see the NHS’s costs of treating the disease rise to as much as £465m a year.

The British Association of Dermatologists (BAD) said the greatly increased number of people with NMSC would be mainly due to prolonged exposure to UV rays causing cancer years afterwards. “There is no single cause [of NMSC]. But the UK has an ageing population and as we get older skin cancers become common, particularly NMSC, which is largely caused by cumulative sun exposure,” said Nina Goad, a spokeswoman for the BAD

theguardian


Gut bacteria associated with cancer immunotherapy response in melanoma

Diversity, composition of microbiome tied to tumor shrinkage from anti-PD1 treatment

UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER

IMAGE
IMAGE: THIS IS JENNIFER WARGO, M.D.

CREDIT: MD ANDERSON CANCER CENTER

Melanoma patients’ response to a major form of immunotherapy is associated with the diversity and makeup of trillions of potential allies and enemies found in the digestive tract, researchers at The University of Texas MD Anderson Cancer Center report at the ASCO-Society for Immunotherapy in Cancer meeting in Orlando.

EUREKALERT


MELANOMA – what you need to know
Hearing the words “It’s cancer” can be overwhelming. Often, people are too stunned to be able to ask physicians for the information they need. When discussing your diagnosis and treatment options with your physician, it can be helpful to have questions prepared ahead of time, so that you don’t forget anything important. Take a pen and paper to write down the answers, or a portable tape recorder so that you can play back the answers later. Studies have shown that people who are more informed about their cancer have a more positive attitude and respond better to treatmentskincancer.org


AACR 2017: Ipilimumab/CVA21 Combination Treatment Shows Promise in Advanced Melanoma

Treatment with a combination of ipilimumab (Yervoy) and coxsackievirus A21 (CVA21; Cavatak) led to durable responses in a number of patients with advanced melanoma, including some whose melanoma had progressed despite prior treatment with an immune checkpoint inhibitor, and fewer-than-anticipated adverse events, according to results from a phase Ib clinical trial presented by Curti et al at the 2017 American Association for Cancer Research (AACR) Annual Meeting

acopost.com


 

Hospital parking fees set to be quashed for cancer patients
The move will save millions of euro for cancer and other priority groups

Cancer patients are expected to have parking charges quashed after a former Lord Mayor has signalled a local authority are to give the move the green light.

The move will save millions of euro for cancer and other priority groups attending hospitals in the capital.

Former Dublin Lord Mayor and Independent councillor Christy Burke has succeeded in getting a motion passed in City Hall instructing hospitals to review parking fees for cancer patients and others with serious health issues.

dublinlive.ie


Pathology ReportsPinterest
What is a pathology report?

A pathology report is a document that contains the diagnosis determined by examining cells and tissues under a microscope. The report may also contain information about the size, shape, and appearance of a specimen as it looks to the naked eye. This information is known as the gross description.

A pathologist is a doctor who does this examination and writes the pathology report. Pathology reports play an important role in cancer diagnosis and staging (describing the extent of cancer within the body, especially whether it has spread), which helps determine treatment options.

Read more

www.cancer.gov


questionnaire
Patient perspective about cancer drugs cost
This questionnaire is part of follow-up study (published in Lancet Oncology in Jan 2016) about expensive cancer drugs actual costs in Europe. Besides the update of cancer drug prices, the additional value is expected from the patient perspective. Based on literature, the pricing system of cancer drugs is not considered to be transparent. Patient as a final consumer is influenced by the cost, but it is not clear why is that so and what could be the potential solutions to overcome these problems. The aim of this survey is to cast light how expensive cancer drugs influence the patient through patient representatives (ECPC members). Desired outcome would be to map the current situation in European countries and find with which factors they correlate. Doing so we also hope to raise the awareness and highlight critical issues concerned to patient burden due to cost of drugs. The expected outcome would be valuable for decision makers by transmitting the current realistic situation among European Union member states. With any questions or additional comments please contact r.ots@nki.nl.
to fill out the questionnare just follow this link
docs.google.com

Advanced Melanoma Patients with Initial BRAF Therapy Resistance Can Be Treated Again, Study Finds
Advanced Melanoma Patients with Initial BRAF Therapy Resistance Can Be Treated Again, Study Finds
 People with advanced and metastatic melanoma who had become resistant to BRAF-targeted therapy were successfully retreated with this therapy after a three-month pause, researchers in Belgium reported.

A liquid biopsy tool, Idylla ctBRAF Mutation Assay, developed by Biocartis, was used to monitor patients’ mutational status. The non-invasive biopsy assay detects tumor DNA circulating in the blood.

The study, “Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial,” was led by Bart Neyns from the University Hospital Brussels, and published in The Lancet Oncology.

Patients with BRAFV600-mutant melanoma benefit from a treatment that combines BRAF and MEK inhibitors, but resistance and disease progression eventually develops in most.  However, preclinical studies and case studies have indicated that acquired resistance to BRAF inhibition may be reversible, and the researchers decided to challenge a tumor again with these inhibitors to see if the treatment might be effective in certain patients.

melanomanewstoday.com


UCD The Patient Voice in Cancer Research III
DATE AND TIME

Wed, April 12, 2017

9:00 AM – 1:30 PM IST

Inviting cancer survivors and their families to join researchers, health care professionals and patient advocates to discuss placing the patient voice at the heart of the cancer research agenda.

9:00am Welcome & refreshments

9.45am “Creating the roadmap for Patient Voice: Update of progress to date”
Dr Amanda McCann, Chair, Patient Voice Committee

10.30am “Is there a clinical trial for me?”
Speaker presentations & discussion forum including:
Eibhlin Munroe, CEO, Clinical Trials Ireland – “How to find out about Trials and who do you Ask?”
Derick Mitchell, CEO, Irish Platform for Patient Organisations, Science & Industry

12.00pm “Crowdsourcing histological scoring: Patients vs Pathologists”
Is enlisting help from the public a sufficiently accurate method to score tissue samples that inform treatment?
Facilitated by Dr Aurelie Fabre, Consultant Histopatholgist, St Vincent’s University Hospital & Dr Amanda McCann, Head of Pathology & Director, UCD Centre in Translational Oncology

12.45pm Light lunch & address by Professor Patrick Murray, Dean of Medicine & Head of UCD School of Medicine

1.30pm Attendees are invited to join researchers for the survivorship lap of Relay for Life UCD (2pm start, Devlin pitch, UCD)

Organised by UCD School of Medicine, UCD Conway Institute, BREAST-PREDICT & Systems Biology Ireland in conjunction with Relay for Life UCD & the Irish Cancer Society

#passthepurple

FAQs

What are my transport options getting to the event?

Information on getting to UCD is available on http://ucdestates.ie/commuting/.

The closest vehicular entrance to UCD Charles Institute is via the Clonskeagh entrance (Wynnward Drive).

Please note that the internal road barriers are in place on campus during peak hours. It will not be possible to drive from the N11 entrance to UCD around to the Institute building.

What are my parking options on campus?

Information on parking in UCD is available on http://ucdestates.ie/commuting/.

The closest visitor carpark to UCD Charles Institute is behind the UCD Sports Centre. Parking fee is €1 per hour to a maximum of €3 per day.

There are 5 diasabled parking spaces directly to the rear of UCD Charles Institute and Systems Biology Ireland building. http://ucdestates.ie/commuting/getting-here/driving/parking/disabled/

There will be a limited number of reserved parking spaces to the rear of the UCD Charles Institute and Systems Biology Ireland. Allocation on a first-come-first-served basis by email to patientvoice@ucd.ie

Where is UCD Charles Institute located?
UCD Charles Institute is building 14, grid C5 on the UCD Belfield campus map – http://ucdestates.ie/information/ucd-maps/
Look out for our ‘Relay for Life UCD’ volunteers who will be providing directions on the day.

How can I contact the organiser with any questions?

Contact: patientvoice@ucd.ie or Elaine Quinn [E:elaine.quinn@ucd.ie; T:(+353-1) 716 6706]

LOCATION

UCD Charles Institute (building 14)

University College Dublin

Belfield

4 Dublin

www.eventbrite.com


Melanoma Gene Study May Help Predict Who Will Benefit from Immunotherapy
Melanoma Gene Study May Help Predict Who Will Benefit from Immunotherapy
 While high mutation load in metastatic melanoma is often associated with better responses to immune checkpoint inhibitors, researchers have found that loss of certain genomic regions in metastatic melanoma can bring about resistance to such therapies.

In addition, treatment with the anti-CTLA-4 Yervoy (ilipimumab), even if it fails, might prime the immune system to successfully respond to the anti-PD-1 therapy Opdivo (nivolumab).

The findings may help doctors predict who will benefit from immunotherapy and understand the mechanisms of therapeutic resistance to improve patient management and outcomes.

melanomanewstoday.com


GlaxoSmithKline fined $3bn after bribing doctors to increase drugs sales
Sales reps in the US encouraged to mis-sell antidepressants Paxil and Wellbutrin and asthma treatment Advair
GlaxoSmithKline
GlaxoSmithKline has admitted to corporate misconduct in the US. Photograph: Toby Melville/Reuters

The pharmaceutical group GlaxoSmithKline has been fined $3bn (£1.9bn) after admitting bribing doctors and encouraging the prescription of unsuitable antidepressants to children. Glaxo is also expected to admit failing to report safety problems with the diabetes drug Avandia in a district court in Boston on Thursday.

www.theguardian.com


KEYTRUDA (pembrolizumab) – Risk of Severe Skin Reactions: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Health Canada is currently working with the manufacturer to include this safety information in the Canadian Product Monograph.

  • Cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), some with fatal outcomes, have been reported in patients treated with KEYTRUDA (pembrolizumab).
  • Healthcare professionals are advised to:
    • counsel patients about the benefits and risks of KEYTRUDA, including the risk and early symptoms of SJS and TEN.
    • suspend KEYTRUDA treatment and refer for immediate specialized evaluation and treatment if a patient reports any severe skin reaction, or in a case of suspected SJS or TEN.
    • permanently discontinue KEYTRUDA if SJS or TEN is confirmed.
  • Health Canada is currently working with the manufacturer to include this safety information in the Canadian Product Monograph.
  • healthycanadians.gc.ca

The secret to curing cancer could lie in treatments that ‘supercharge’ immune systems

Pioneering research is targeting cancer cells – by reprogramming our defences

Tom Gauld

In September 2012, Adrian Webb’s wife spotted that a mole on his back had changed colour. It was a melanoma and it had spread to his lymph nodes. Despite a number of surgeries and an intensive course of radiation therapy, the cancer continued to spread to his lungs, bowel, liver and spine. “I was given 12 months to live,” says the 51-year-old.

www.wired.co.uk


Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma

 

Researchers assessed tumor samples to better understand why CTLA-4 and PD-1 inhibitors are only effective in some patients with melanoma.
Researchers assessed tumor samples to better understand why CTLA-4 and PD-1 inhibitors are only effective in some patients with melanoma.

Whole-exome sequencing of tumor biopsies from metastatic melanoma taken before, during, and after treatment with sequential checkpoint blockade against cytotoxic T lymphocyte antigen-4 (CTLA-4) followed by programmed death receptor-1 (PD-1) revealed loss of multiple tumor-suppressing genes. These genes affect the immune response to immunotherapy and lead to resistance to CTLA-4 and PD-1 inhibitors.1

www.oncologynurseadvisor.com


Choosing adjuvant melanoma therapy remains ‘controversial, tough’
 March 24, 2017

NEW YORK — Interferon and ipilimumab are options for the adjuvant treatment of many patients with melanoma, but data are lacking comparing these two agents, according to a speaker at HemOnc Today Melanoma and Cutaneous Malignancies.

healio.com


Mobile Applications
Now Available on iOS, Android, and the Amazon App Store: Version 3.1

Version 3.1 of Cancer.Net Mobile includes several feature enhancements and improvements, including:

  • Newly designed dashboard – easy access to medications, symptoms, questions, and cancer type information
  • Scheduling features – add any symptom, medication, or question to your calendar to ask at your next appointment
  • Quick links – your saved information is now just one tap away
  • Data entry optimization – enter your information more quickly and seamlessly for easier tracking
  • Enhanced symptom tracking – symptoms plotted by severity on an easy-to-read line graph
  • Filtering capabilities – easily filter medications, questions, and symptoms by attribute

Cancer.Net Mobile is a free app for iOS (iPhone, iPad) and Android and features:

  • Spanish-enabled! Users whose primary device language is set to Spanish are able to use all of the award-winning features of the app in their native language, as well as select oncologist-approved cancer information.
  • Get Information – up-to-date guides on 120+ types of cancer, including treatment, managing side effects, cost of care, and living with cancer, as well as the latest videos, podcasts, and Cancer.Net Blog posts
  • Record Questions – easily jot down questions for your doctors and record their answers
  • Log Medications – take photos of medication labels and bottles. Log dosage, frequency, and prescribing doctor
  • Track Symptoms – note symptoms and side effects. Automatically plot severity, date, and time in an easy-to-read line graph
  • Scheduling – add questions, symptoms, or medications to your mobile device calendar
  • Link Questions – link any questions to ask at your next appointment with a current symptom or medication
  • Optional passcode lock
  • Optional iCloud backup for the questions, medications and symptoms entered into Cancer.Net Mobile (on iCloud-enabled iOS devices)
  • cancer.net

Redheads’ Gene May Be Missing Link Between Melanoma and Parkinson’s

Posted by

Kristen Teesdale

,

Redheads' Gene May Be Missing Link Between Melanoma and Parkinson's

A new study published in the Annals of Neurology suggests that redheads may carry a gene variant that increases the risk of both Parkinson’s disease (PD) and melanoma. Researchers have long known that having either PD or melanoma heightens the chances of developing the other condition, but it’s been unclear exactly why. Results from the MJFF funded study, led by Xiqun Chen, MD, PhD, of the Massachusetts General Institute for Neurodegenerative Disease, indicate that the MC1R gene variant, which is responsible for red hair and fair skin, may be to blame.

michaeljfox.org


Call for cancer patients to be exempt from hospital parking charges

Despite a petition of over 3,000 signatures and a national campaign in December, no hospital in Ireland has changed its parking pricing policy for cancer patients.

The Irish Cancer Society is calling for free or subsidised parking for all cancer patients receiving treatment.

Earlier this month, the Irish Cancer Society contacted every hospital that provides cancer treatment in Ireland and found no difference between the 2016 and 2017 rates.

kildarenow.com


Advanced melanoma patients in Cork and Kerry to have access to new therapies

Advanced melanoma patients in Cork and Kerry can access ground-breaking therapies not available on the open market thanks largely to the work of clinicians who set up the first dedicated melanoma multidisciplinary team (MDT) in the country, writes Catherine Shanahan

The South West Melanoma MDT, consisting of dermatologists, plastic surgeons, surgical oncologists, medical oncologists, radiologists, pathologists, radiotherapists, research nurses, celebrates its 10 anniversary this year.

irishexaminer.com


Reviving tired T cells when immuno-oncology drugs fail

Checkpoint inhibitors like Merck’s Keytruda (pembrolizumab) are designed to stimulate the immune system’s T cells to recognize and attack cancer cells. Problem is, they don’t work for many patients, and no one has been able to pinpoint exactly why that is. Now scientists at Emory say they’ve found a clue, in an immune protein called CD28.

fiercebiotech.com


Sun Protection by Beach Umbrella vs Sunscreen With a High Sun Protection Factor
A Randomized Clinical Trial

Questions  How well does typical shade from a beach umbrella protect against sunburn and how does it compare with protection provided by sunscreen with a high SPF?

Findings  This single-center, randomized clinical study found that, during 3½ hours of sun exposure, 78% of participants under shade from a beach umbrella developed a sunburn vs 25% of participants using sunscreen. Neither shade nor sunscreen alone completely prevented sunburn.

Meaning  Shade from a beach umbrella alone does not provide sufficient protection for extended exposure to UV rays; indicating a combination approach may be needed for optimal protection from UV rays.

jamanetwork.com


‘The cancer is not my enemy’: A mindful healing
 In June of last year my wife and I were looking forward to a family celebration of our 50th wedding anniversary. Life was good and little did we realise that a storm was brewing that was to rock our lives. It all started so innocently. I had a small growth on my forehead removed and within three days I was being told that the biopsy indicated I had a rare melanoma cancer in my head and possibly in my neck. I was scheduled for an urgent operation the following Monday.

The vitamin D question: what’s the best advice?

A diagnosis of cancer can prompt a patient to make all kinds of changes. Many adopt a holistic attitude to their health, altering their lifestyle, and especially their diet, in the hope it will help. Some start taking supplements. And one supplement in particular is at the centre of a simmering controversy about whether it might help or harm. That’s vitamin D.

cancerworld.net


Treatment Options for Stage 0 Melanoma

The standard of treatment for Stage 0 melanoma (in situ) is re-excision of the original site with a surrounding area of normal-looking skin being taken. The standard amount of normal skin is 0.5 centimeters in every direction around the original cancer. This procedure may be done in a doctor’s office under local anesthetic.

aimatmelanoma


A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915)
ClinicalTrials.gov Identifier:
NCT03068455
First received: February 27, 2017
Last updated: March 1, 2017
Last verified: March 2017
The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab is more effective than nivolumab or ipilimumab alone in treatment of patients after complete resection of stage IIIb/c/d or stage IV melanoma who are at high risk of relapse

Vitamin D levels can affect aggressiveness of melanomas

Lower levels of vitamin D are associated with thicker tumours and poorer survival, according to a speaker at the British Association of Dermatologists annual meeting.

pharmaceutical.com


Monotherapy Versus Combination Therapy Approaches in Melanoma

Michael A. Postow, MD: When we think about immune therapy for melanoma, our major initial decision is, do we give this patient a single PD-1 drug, like pembrolizumab or nivolumab, or do we give this patient a combination of immune therapy drugs, such as the combination of nivolumab with ipilimumab? That’s the major decision that we come across.

Onclive.com


Absent tumor-suppressors allow melanoma to thwart immunotherapy

It’s what’s missing in the tumor genome, not what’s mutated, that thwarts treatment of metastatic melanoma with immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center report in Science Translational Medicine.

Read more at: https://medicalxpress.com


Some Melanoma Survivors Still Seek Out the Sun

THURSDAY, March 2, 2017 (HealthDay News) — Even after surviving the potentially deadly skin cancer melanoma, some people continue to go out in the summer sun without protection.

 That’s the stunning finding of a study of more than 700 melanoma survivors that revealed that 20 percent of them had suffered a sunburn in the past year. And only 62 percent said they “often” or “always” wore sunscreen when they were outside on a summer day.

But many melanoma survivors are more vigilant about sun protection than other people their age, the study also found.

health.com


Melanoma Case Studies Illustrate Factors in Choosing Targeted Therapies
What factors do you consider when determining treatments for patients like this who are BRAF mutated?

The factors to think about are disease burden, LDH, and the desire of the patient to deal with toxicity, because that is often a big issue. This is a patient who was intermediate, meaning there was an intermediate disease burden, although the LDH was normal and they could have gone either way. You could have reasonably put someone like this on BRAF/MEK inhibition, or you could have put them on immunotherapy. It all depends on the patient’s individual choice that makes the difference.

Onclive.com


Melanoma with liver metastasis: a review on treatment options
In a nutshell

The authors reviewed different treatment options available for melanoma patients with cancer spread to the liver.

Some background

In advanced melanoma (stages 3 and 4), cancer has spreads from the skin to other parts of the body. This is known as metastasis. Treatment of liver metastasis in advanced melanoma still remains a challenge. The progression of skin melanoma and eye melanoma follow distinctly different courses. Spreading of cancer to the liver is very common in eye melanoma. 89% of patients who develop metastases of eye melanoma have cancer spread to the liver. In contrast, only 10-20% of metastatic skin melanoma patients have cancer spread to the liver.

Understanding of the different treatment options available for melanoma that has spread to the liver will aid in improving the survival outcome of these patients.

medivisor.com


CT Scan vs. PET Scan

CT scan (computer tomography) and PET scan (positron emission tomography) are different but related imaging techniques. A PET scan uses nuclear medicine imaging to produce a three-dimensional picture of functional processes in the body. PET scans provide metabolic information and are increasingly read alongside CT or MRI (magnetic resonance imaging) scans, which provide anatomic information.

diffen.com


Gut bacteria associated with cancer immunotherapy response in melanoma
Melanoma in skin biopsy with H&E stain — this case may represent superficial spreading melanoma. Credit: Wikipedia/CC BY-SA 3.0

Melanoma patients’ response to a major form of immunotherapy is associated with the diversity and makeup of trillions of potential allies and enemies found in the digestive tract, researchers at The University of Texas MD Anderson Cancer Center report at the ASCO-Society for Immunotherapy in Cancer meeting in Orlando.

Medicalxpress.com


Vaccine therapy + dasatinib for the treatment of patients with stage IIIB–IV melanoma

Melanoma remains a significant health concern worldwide, with disease incidence continuing to rise over the past four decades. In the USA alone in 2016, the American Cancer Society estimates that 76,380 new cases of melanoma will be diagnosed, with 10,130 patients succumbing to this disease. Although early stages of the disease are surgically curable and adjuvant therapy of high-risk disease is moderately effective in preventing recurrence.

oncology-central.com


The role of immunotherapy in treating solid cancers

Engaging the body’s own immune system in controlling cancer has long been an aspiration for cancer researchers and clinicians. This overview looks at progress towards that goal, and how it is changing the paradigm of cancer treatment.

cancerworld.net


Cancer patients not given painkillers soon enough, study finds

GPs are increasing the anguish of cancer patients by depriving them of pain relief, research has suggested.

A study found that terminal patients in the UK were often not prescribed powerful opioids such as morphine until nine weeks before their death.

Many would have been suffering pain for much longer, said the authors. Doctors were waiting too long before allowing patients with advanced cancer to have the drugs, they claimed.

the guardian


Idera Pharmaceuticals (IDRA) Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combination with Ipilimumab

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today is reporting additional data from the dose-escalation phase of its ongoing Phase 1/2 clinical trial of intratumoral IMO-2125, an agonist of TLR9 in combination with ipilimumab or pembrolizumab for treatment of patients with metastatic melanoma with disease that is refractory to PD-1 inhibitors.

streetinsider.com


Familial melanoma linked to many other discordant cancers

Takeaway

  • Family history of cutaneous melanoma is a risk factor for melanoma and also appears to be associated with other discordant cancers.

Why this matters

  • These findings provide new leads and incentives to investigate genetic association with other cancer types, aside from those that have already been established.
  • univadis.com

Immunotherapy Needs a New Math

Created by a panel of experts, the Evidence Blocks incorporate “the acquisition cost of the agent, required supportive therapy, the likelihood and expense of managing adverse events (AEs), and site of care, among other factors.” Carlson and McClure said the affordability metric does not specifically weigh costs versus benefits or costs versus toxicity; however, they said the Evidence Blocks have high utility for considering multiple measures of value at one time, including “efficacy, safety, data quality, data consistency, and affordability.”

Onclive.com


An Open-Label Study of Atezolizumab in Advanced Solid Tumors

The primary efficacy objective for this study is to evaluate non-progression rate (NPR) at 18 weeks in participants with advanced solid tumors treated with atezolizumab, defined as the percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) as assessed by the Investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), or according to disease-specific criteria for prostate cancer and malignant pleural mesothelioma.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below

clinicaltrials.gov


Antibiotic Use May Damper the Efficacy of Checkpoint Inhibitors

Use of antibiotics up to a month before treatment with a checkpoint inhibitor may decrease the efficacy of the immunotherapy agent, results of a retrospective analysis show. The analysis, presented during a presscast of the 2017 Genitourinary Cancers Symposium, raised suspicion of the relationship between gut microbiota and antibiotics and their effect on immune checkpoint blockade agents.

Onclive.com


The Future Management of Melanoma

Robert H.I. Andtbacka, MD, CM: I guess many of these unmet needs in the stage IV patient population also applies to the stage III patient population. And I think that additionally, there, it’s really the whole question of neoadjuvant therapy, as we talked about. Michael A. Davies, MD, PhD: I think the other question there is—and this is applicable not only to stage III, but to earlier stages—can we do a better job of identifying which patients need aggressive intervention versus which patients are those who really won’t have the disease relapse? And then the question is, can we take what we’ve learned about the molecular biology and the immunology of this cancer to really personalize the management of earlier stages of disease as well?

Onclive.com


Gamma Knife Radiosurgery for 5 to 10 Brain Metastases: A Good Option for Upfront Treatment

Brain metastases develop in approximately 10% to 20% of cancer patients each year in the United States (~500,000 patients). With insufficient brain imaging to detect the number and location of the metastases, clinicians previously had no option other than empiric whole-brain radiation therapy (WBRT).[1,2] The development of better systemic targeted cancer therapies coupled with the recognition of the long-term deleterious effects of WBRT has spurred rapid expansion of the use of stereotactic radiosurgery (SRS).

Cancer Network


MELANOMA RESEARCH BREAKTHROUGH GIVES HOPE TO TREATMENT

A QUT-driven project has identified the way in which melanoma cells spread, opening up new pathways to treatment via drugs to ‘turn off’ the invasive gene.

Led by Dr Aaron Smith from QUT’s School of Biomedical Sciences within the Institute of Health and Biomedical Innovation at the Translational Research Centre, the project results have just been published in international journal EBiomedicine and could offer a new avenue for cancer treatment.

Oncology news


Association of Indoor Tanning Frequency With Risky Sun Protection Practices and Skin Cancer Screening

Question  How is indoor tanning frequency associated with behaviors related to skin cancer prevention?

Findings  This cross-sectional study using data from the US 2015 National Health Interview Survey found that young adults who frequently tanned indoors were significantly more likely to never/rarely use protective clothing or shade compared with young adults who did not tan indoors. Similar findings were observed among women.

Meaning  In 2 groups with high indoor tanning prevalence (young adults and women), frequent indoor tanners often exhibited a concurrent tendency to practice poor sun protection, which may increase their risk of skin cancer beyond the risk associated with indoor tanning alone.

jamanetwork.com


No Sugar, No Cancer? A Look at the Evidence

There’s a lot of confusing and misleading information on the Internet about the relationship between sugar and cancer. The notion that refined sugar causes cancer or that cutting sugar from the diet is a good way to treat cancer are two common — and incorrect — claims that turn up in a Google search.

That’s unfortunate, because there is important, real science to understand about diet and cancer. To help sort out fact from fiction, we spoke with MSK President and CEO Craig Thompson, who studies the relationship between metabolism and cancer.

mskcc.org

Understanding Your Pathology Report: Melanoma
What is a pathology report?

A pathologist is a doctor who specializes in diagnosing diseases by examining tissue from the body. You will probably never meet the pathologist, but samples of your melanoma tissue, removed during surgery or biopsy, will be sent to him or her for review. The pathologist prepares a report of their findings, which is called the pathology report. This report contains important information about the tumor that is used to make treatment decisions. You should request a copy of this report and keep it in your personal medical files.

oncolink.org

Underlying Autoimmune Disease Is Not a Contraindication to the Use of Ipilimumab

The use of immune checkpoint inhibitors, a new class of anticancer agents with a mechanism of action based on augmenting existing tumor-specific immunity, is often restricted or avoided in patients with autoimmune disease. The rationale for this restriction is that the autoimmune toxic effects observed with the use of these agents could be amplified in patients with rheumatic diseases. Moreover, patients would have an exacerbation of their underlying inflammatory condition.

jamanetwork.com

Tools for modelling and predicting cancer progress

Every cancer follows its own complex path. An EU-funded project is developing experimental tools and a computer model to generate and test ideas on the combined impact of the body’s cell and chemical processes on cancer progress. The findings should one day help researchers and SMEs find better-targeted drugs faster.

europa

Non-profit drug development could cut cost of cancer medicines

Universities should work with new forms of commercial partner to take their own cancer drugs to market and drive down the ‘spiralling’ cost of new medicines, leading experts propose.

A high-profile commentary warns that the price of cancer drugs is now rising so fast it threatens the whole financial viability of cancer treatment – particularly as the increased use of drug combinations multiplies costs.

The authors propose that expert drug discovery teams in academia could develop cancer drugs more cheaply by working with new forms of private enterprise as an alternative to the traditional pharmaceutical industry model.

‘$100,000 cancer drugs’

The commentary – How much longer will we put up with $100,000 cancer drugs? – puts forward a series of radical solutions to disrupt the drug discovery and development system and provide real competition for the conventional pharmaceutical industry approach.

icr.ac.uk

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Cancer immunotherapy can induce long lasting responses in patients with metastatic cancers of a wide range of histologies. Broadening the clinical applicability of these treatments requires an improved understanding of the mechanisms limiting cancer immunotherapy. The interactions between the immune system and cancer cells are continuous, dynamic, and evolving from the initial establishment of a cancer cell to the development of metastatic disease, which is dependent on immune evasion. As the molecular mechanisms of resistance to immunotherapy are elucidated, actionable strategies to prevent or treat them may be derived to improve clinical outcomes for patients.

Cell.com

Cancer ‘Scanxiety’ Is a Real (Terrifying) Thing

It’s a not part of the medical lexicon (at least not yet), but “scanxiety” is a word that cancer care providers would do well to know.

That’s because it negatively affects patients’ quality of life, may undermine follow-up care plans, and can even lead to unnecessary treatment, according to interviews with physicians and a review of the sparse medical literature on the subject.

Scanxiety is cancer patients’ fear and worry associated with imaging, both before and after a test (before the results are revealed).

Medical.net

Cúnamh Cancer Support Group

Cunamh Cancer Support are holding a two part workshop on Lymphoedema in The River Lee Hotel, Monday 27th of February and Monday 6th of March, 11.30am-1.30pm.

This workshop will be covering the 4 cornerstones of prevention or practical care of Lymphoedema following cancer treatment.Includes exercises and breathing techniques.

Free of charge. Booking essential.
Contact; Meadbh Mac Sweeney
The Lymph Clinic
Cork Clinic
Western Road.
021 4347351.
Email: meadbh@thelymphclinic.ie.


Dishing the dirt on detox

A self-confessed glutton, Jay Rayner has always been wary of the ‘January detox’. But after talking to experts and sampling some of the products, he’s discovered the truth is even worse than he imagined

theguardian

Pediatric Melanoma
About Pediatric Melanoma

Melanoma, the most dangerous form of skin cancer, is on the rise in both adults and children. Although pediatric melanoma is quite rare, a 2013 study published in the journal Pediatrics indicated that diagnoses are rising in the U.S., particularly in the age group of 15-19 years, by approximately 2% each year. The National Cancer Institute estimates that approximately 500 children in America are diagnosed each year. Additionally, a 2015 study published in the Journal of Investigative Dermatology contained a comprehensive genomic analysis of pediatric melanoma – finding unique genomic features for each of the three subtypes (discussed below) of pediatric melanoma – and suggests compelling evidence that UV exposure may play more of a role than initially thought in this disease, primarily regarding conventional pediatric melanoma.

Melanoma.org

Diagnosing Melanoma

Diagnosing melanoma can be a difficult task, even for a trained dermatologist or physician. Because the symptoms are not always obvious, it is critical that you pay close attention to caring for your skin, and notify your doctor right away if you have concerns or find a suspicious mole – especially if you have a family history of melanoma.

Melanoma.org


Experts predict melanoma death rates will fall by 2050
But numbers of deaths will increase unless effective treatments are developed
Date:
January 29, 2017
Source:
ECCO-the European CanCer Organisation
Summary:
By 2050 the death rates from malignant melanoma will have decreased from their current levels but the numbers of people dying from the disease will have increased due to the aging of populations. However, if new treatments for the deadly skin cancer prove to be effective, the numbers of deaths could fall too, according to research.
sciencedaily

Understanding Your Pathology Report: Melanoma
 What is a pathology report?

A pathologist is a doctor who specialises in diagnosing diseases by examining tissue from the body. You will probably never meet the pathologist, but samples of your melanoma tissue, removed dspecialisesry or biopsy, will be sent to him or her for review. The pathologist prepares a report of their findings, which is called the pathology report. This report contains important information about the tumor that is used to make treatment decisions. You should request a copy of this report and keep it in your personal medical files.

 

FDA Approved Drugs for Melanoma

In this section, learn about FDA (U.S. Food and Drug Administration) approved drugs for melanoma, as well as suggestions for managing the side effects associated with these drugs.

FDA Approved Drugs for Melanoma


Immune Cells Delivered Drugs Specifically to Tumors in Lab Study

Using immune cells as carriers for nanoparticle-containing anti-cancer drugs may be a promising strategy to develop targeted therapies that affect tumor cells without damaging healthy cells.

Indeed, loading immune cells with nanoparticles containing Zelboraf (vemurafenib), an approved melanoma therapy, led to the targeted delivery of these nanoparticles into circulating melanoma cells, which effectively killed the cancer cells.

melanomanewstoday

SD-101, Pembrolizumab Combo Shows Promise in Melanoma

Results from a safety, tolerability, and dose escalation phase Ib/II study involving intratumoral SD-101 and pembrolizumab (Keytruda) have demonstrated that the combination was well-tolerated with no dose-limiting toxicities in early-stage melanoma, according to lead researcher, Antoni Ribas, MD, PhD.

Targetedonc.com

Encorafenib/Binimetinib a Potential New Treatment Option for BRAF-Mutant Melanoma

BRAF inhibitor encorafenib (LGX818) combined with the MEK inhibitor binimetinib (MEK162) reduced the risk of progression or death by 46% compared with vemurafenib (Zelboraf) for patients with BRAF-mutant unresectable melanoma, according to findings from cohort 1 of the phase III COLUMBUS trial.

Targetedonc.com

Cancer Immunotherapy: a Step Change in Cancer Treatment

This course will teach you about the power of your immune system and how new immunotherapies are transforming cancer treatment.

Futurlearn

Demystifying Targeted Cancer Treatments

Thanks to ground-breaking research in cancer over the past 20 years, new, more targeted treatments have been developed that are changing the way we treat cancer, and providing new hope for patients.

This free online course from Cancer Research UK, will explore the science behind new targeted cancer treatments, how they work, and the patients they benefit. We’ll look at the side effects these treatments can cause and understand the impact they have on patients’ quality of life. Then discover some of the innovative approaches on the horizon and debate the future of cancer treatment.

Develop your knowledge
Futurlearn

Managing Side Effects

While you are undergoing immunotherapy, targeted therapy, chemotherapy, and/or radiation therapy, you may experience side effects that may make eating more difficult, food less appealing, and tasks more difficult to accomplish. Side effects vary in severity and duration from person to person. They may also vary with treatments and during different phases of treatment and recovery. Often the most severe side effects occur in the early days of treatment and gradually subside as your body adjusts to treatment. Most side effects disappear after treatment ends. Unfortunately, growing cancer can cause similar symptoms, and sometimes it is difficult to distinguish between side effects caused by the treatment and the progression of the disease.

Aim at Melanoma

 Adjuvant Therapy Options in Advanced Melanoma

obert H.I. Andtbacka, MD, CM: We had an informed discussion with the patient, went through all the risk, benefit, and alternatives. We did have a neoadjuvant study available, but the patient opted to undergo surgical resection, and we did that.

Onclive.com

Diagnosing melanoma
Cases highlight grey areas

Dermatologists and dermatopathologists can address the challenges of diagnosing and treating melanomas by using combination stains, a growing assortment of genetic tests and even new prognostic indicators, says Whitney A. High, M.D., J.D., M.Eng., an expert who spoke at the 2016 Fall Clinical Dermatology Conference (October 2016, Las Vegas).

dermatologytimes

Sequencing Decisions and Multidisciplinary Care in Metastatic Melanoma

Georgina Long, MD: In our institution, the factors that really play into this are volume of brain disease and whether they have extracranial disease. How many brain metastases do they have? How big are the brain metastases? We discuss it in a multidiscipline-retained meeting. We know the response rate with a single-agent BRAF inhibitor.

Onclive.com

Quitting EU regulator ‘would leave UK waiting longer’ for new drugs

Drug firms say leaving EMA could mean Britons having to wait a year longer than EU citizens for newly-developed medicines

theguardian

Melanoma mutation likes fat for fuel.

Cancer cells love glucose, the simple sugar the body uses for energy, so a high-fat, low-carb diet should starve them, right?

Not so fast. Research in mice suggests that melanomas and other cancers driven by a particular mutation (BRAF V600E) will grow faster in response to a high-fat diet. In addition, lipid-lowering agents such as statins curb these cancers’ growth, even in the context of a more normal diet.

news.emory

Partners Should Be Trained to Check for Mole Irregularities

A new study from Northwestern Medicine shows the advantages of partners frequently checking for potentially dangerous moles, after receiving training to do so.

melanomanewstoday

UVEAL MELANOMA
Ireland has possibly highest incidence in the world

Ireland may have the highest incidence of uveal melanoma in Europe and possibly the world, the 2016 Irish College of Ophthalmologists Annual Conference in Killarney, Ireland, heard. Caroline Baily MRCSI (Ophth), MRCGP, DO, FEBO, Specialist Registrar in Ophthalmology, Royal Victoria Eye and Ear Hospital (RVEEH), Dublin, Ireland, presented the findings of the first study on the epidemiology of uveal melanoma in Ireland at the conference.

eurotimes

Chemical Compound May Help Reduce the Spread of Melanoma

The deadly skin cancer, melanoma, will claim the lives of 10,130 people in the United States in 2016. There is a lot of interest in a new treatment that kills approximately 90% of melanoma cancer cells, an astounding accomplishment for Richard Neubig, MD, PhD, who serves as chairperson of pharmacology toxicology at Michigan State University.

oncotherapy

Immune Cells Delivered Drugs Specifically to Tumors in Lab Study

Using immune cells as carriers for nanoparticle-containing anti-cancer drugs may be a promising strategy to develop targeted therapies that affect tumor cells without damaging healthy cells.

melanomanewstoday

Pediatric Melanoma Diagnosis

Most melanomas are diagnosed with a biopsy. A pathologist or dermatopathologist will examine the biopsy under the microscope. If it comes back as a melanoma, surgeons may perform another surgery to ensure there are clear margins – the term used for the complete removal of the lesion. Depending on the diagnosis.

Melanoma.org

How Melanoma Develops

Melanoma develops in a manner similar to other cancer types. A cell’s DNA genes, which control cell division and reproduction, become damaged. The damaged genes cause the cell to divide and grow without control or order, eventually becoming a malignant tumour

Aim at Melanoma

The dying officer treated for cancer with baking soda

The father of the alkaline diet, Robert O Young, is hailed as an inspiration by one of the UK’s most popular food writers, Natasha Corrett, but he faces a jail sentence for practising medicine without a licence. One patient who believed he could cure her cancer, British army officer Naima Houder-Mohammed, paid thousands of dollars for his alkaline treatment, which consisted mainly of intravenous infusions of baking soda.

In May 2009 Naima Houder-Mohammed was commissioned as a captain in the British army. The following year, tragedy struck. Naima was diagnosed with breast cancer.

BBC news

Emerging Immunotherapy Combinations for Melanoma

Video

Onclive.com

Diagnosing melanoma

Dermatologists and dermatopathologists can address the challenges of diagnosing and treating melanomas by using combination stains, a growing assortment of genetic tests and even new prognostic indicators, says Whitney A. High, M.D., J.D., M.Eng., an expert who spoke at the 2016 Fall Clinical Dermatology Conference (October 2016, Las Vegas).

dermatologytimes

Melanoma Treatment Update

With the widespread use of drugs like pembrolizumab and the combination of ipilimumab and nivolumab to treat advanced melanoma in the UK, there is increasing interest in trying to understand why these treatments are not always effective and to develop other treatments that can potentially work if these treatments are not successful.

Melanoma.org

there is now a support group on Facebook specifically for OM patients
To join follow this link
Ocular melanoma Ireland

Melanoma survivors Ireland
melanoma news (survivors)

Under the Skin: A special investigation

In part one, Kylie spoke to patients and the specialist team who are now warning getting burnt as a child can increase your risk of getting skin cancer by 80%.

itv News

My kids saw their brother die so the ‘get cancer’ message upsets them’- Mum criticises controversial cancer ad

A grieving mum who lost her young son to cancer has criticised the new Irish Cancer Society’s ‘get cancer’ ad, calling for it to be removed from TV.

Independent.ie

Patient Selection in Melanoma: Immunotherapy vs Targeted Therapy

Robert H.I. Andtbacka, MD, CM: What about the other factor then? Many of these patients, if they’re 50 years old and they’re working, are coming in for infusions every 2 weeks or every 3 weeks—depending on how you do that—versus taking a pill at home. Does that impact on your decision to have one treatment versus the other in terms of practical reasons, Mike?

Read more or watch video

Onclive.com


 Tumour immunology and immunotherapy

This animation created by Nature Reviews Cancer and Nature Reviews Immunology illustrates how tumour cells are sensed and destroyed by cells of the immune system and how tumours can evolve to evade immune-mediated elimination. Scientists are developing new immunotherapies that help the immune system to ‘fight back’ — the animation explains how these exciting new drugs work.

Youtube

Long-term survival and clinical benefit from adoptive T-cell transfer in stage IV melanoma

The presence of tumor-infiltrating immune cells is associated with longer survival and a better response to immunotherapy in early stage melanoma, but a comprehensive study of the in situ immune microenvironment in stage IV melanoma has not been performed. We investigated the combined influence of a series of immune factors on survival and response to adoptive cell transfer

cancerimmunoroles

Best of Oncology what’s new

This is a very interesting video

oncologyeducation

I’m 26 and was diagnosed with skin cancer. Here’s why it didn’t have to happen

But I knew why. This was my fault.

“I was a stupid teenager who tanned a lot,” I told him.

I got skin cancer because I didn’t think being a fair-skinned redhead was good enough. I wasn’t confident in my natural skin, so I crawled into a tanning bed to cook my pale skin brown.

I got skin cancer because I listened to the messages from advertising and women’s magazines that told me I needed “that healthy glow” to be considered beautiful.

I got skin cancer because in high school all the “popular” girls hit the tanning beds hard before every dance — three times each school year in Kansas. And in college, most of the girls in my sorority tanned regularly, especially before date parties — basically all of the time.

Read full story here here
miamiherald

‘My kids saw their brother die so the ‘get cancer’ message upsets them’- Mum criticises controversial cancer ad

A grieving mum who lost her young son to cancer has criticised the new Irish Cancer Society’s ‘get cancer’ ad, calling for it to be removed from TV

Dolores Grace, from Co Meath lost her 20-year-old son Elliot to cancer, five months after he received the shocking diagnosis.

In an open letter Dolores said she’s writing to the Irish Cancer Society “to urge you to rethink your current advertising campaign”.

Read more

Independent.ie

Under the Skin: A special investigation

In part one, Kylie spoke to patients and the specialist team who are now warning getting burnt as a child can increase your risk of getting skin cancer by 80%.

itv News

Skin Cancer

Many strides in the fight against skin cancer were made in 2016. These developments included progress in research, awareness and prevention. These are the top 5 skin cancer articles of 2016 from Dermatology Times.

Skin bacteria may fuel cancer cell progression A study reveals that toxin-producing bacteria like staphylococcus may fuel CTCL; therefore, antibacterial treatment may slow disease progression. Findings could one day change how you treat patients.

Read more

dermatologytimes

Treatment options for stage III melanoma patients

Description: James Larkin, MD, PhD, of the Royal Marsden NHS Foundation Trust, London, UK, explains the treatment options available for patients with stage III melanoma, which means that the disease has been cured with surgery but there is a risk of it coming back. According to Dr Larkin, treatment options are limited and usually participation in clinical trials is the recommended option for such patients. Last year, there was a trial comparing nivolumab and ipilimumab (IPI), and now there is a trial involving the use of pembrolizumab (PEMBRO) as a treatment option. For patients with stage III melanoma that cannot be removed using surgical means, there are several different treatment options (the use of drugs, for instance), but each patient is usually considered on an individualized basis. Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.

Video

oncologytube.com

Treating Melanoma Through Clinical Trials

Clinical trials are often viewed as the best treatment option for a late-stage (Stage III or Stage IV) melanoma patient, so it is important that you learn about them as a treatment option to help make an informed treatment decision.

Melanoma.org

Exploring advancements in viral immunotherapies and vaccines in the melanoma field

The Future Science Group (FSG) published journal, Melanoma Management, has released a special issue highlighting the advancements made in viral immunotherapies and vaccines in the melanoma field.

EUREKALERT

Our ban the beds 2017 Campaign

Sunbeds are UV-emitting tanning devices and are classified “carcinogenic to humans”

They cause skin cancer when used exactly as intended.

It’s time to follow the Australian lead and ban them completely in Ireland.

Please sign the petition

Sign the petition

Grieving daughter posts tragic photograph of terminally ill mum to raise awareness of deadly skin cancer

Laura Bhasker, 22, from Mulhuddart in Dublin is appealing to others not to take risks in the sunshine – or face leaving their loved ones on their own next Christmas

Mirror.co.uk


 Four Cancer-Killing Viruses To Watch In 2017

Cancer-killing viruses are specially engineered versions of naturally occurring viruses that are programmed to home in on cancer cells and kill them without harming normal tissues. This is a branch of immuno-oncology that has been overshadowed by more fruitful endeavors, such as the immune checkpoint inhibitors Opdivo (nivolumab) from Bristol-Myers Squibb BMY -0.47% and Keytruda (pembrolizumab) from Merck , both of which are now certified cancer blockbusters. But several companies are developing cancer-killing viruses, known in the scientific community as “oncolytic” viruses, and some of those efforts are starting to show promise.

Read more

forbes.com

U.S. Melanoma Rate Is Rising

1 in every 54 Americans will develop invasive form of the skin cancer in their lifetime

WEDNESDAY, Dec. 21, 2016 (HealthDay News) — More Americans are developing the potentially deadly skin cancer known as melanoma than in the past, new research shows.

Webmd.com

Melanoma in Ireland Information Booklet
melanoma in Ireland

E magazine 11-18th News
Melanoma News

To see different types of melanoma just click on the link
types of melanoma

 


The Current Understanding of Biomarkers in Melanoma


Treating Melanoma Through Clinical Trials

Clinical trials are often viewed as the best treatment option for a late-stage (Stage III or Stage IV) melanoma patient, so it is important that you learn about them as a treatment option to help make an informed treatment decision.

Melanoma.org

Exploring advancements in viral immunotherapies and vaccines in the melanoma field

The Future Science Group (FSG) published journal, Melanoma Management, has released a special issue highlighting the advancements made in viral immunotherapies and vaccines in the melanoma field.

EUREKALERT

Managing Immunotherapy Side Effects in Melanoma: Quick Intervention Is Key

Although immunotherapies have been an enormous advance for the treatment of many cancers, they come with their own set of toxicities. Patients should learn how to watch for these side effects and be ready to discuss them with oncology nursing professionals, who will know how to help.

Curetoday.com

Risk of men developing cancer plateaus

A new report says the chances of men being diagnosed with cancer, which had been rising steadily since 1994, may have plateaued.

The National Cancer Registry annual report says that rates for the top three cancers in men – prostate, colorectal (bowel) and lung – are now declining, or static.

However, the report says this was balanced against steady increases in the incidence of lymphomas and melanoma of the skin.

RTE NEWS

Not every melanoma is black

West Australian nurse Amanda Whittle never imagined a small pink mark on her upper arm was anything to be concerned about. The spot didn’t resemble anything she knew about skin cancers. It wasn’t black or raised, hadn’t grown from a mole or freckle and she couldn’t remember it changing shape, size or colour.

Melanoma Institute Australia

The Genetics of Melanoma

How Melanoma Develops

Melanoma develops in a manner similar to other cancer types. A cell’s DNA genes, which control cell division and reproduction, become damaged. The damaged genes cause the cell to divide and grow without control or order, eventually becoming a malignant tumor.

In the case of melanoma, the damage to the DNA is usually caused by overexposure to ultraviolet (UV) radiation, and the affected cells are melanocytes, which produce the pigment melanin. The first tumor that develops is usually located in the skin. If not caught, melanoma will grow and spread along the epidermis before penetrating deeper layers of the skin and eventually coming into contact with lymph and blood vessels.

Read more

Aim at Melanoma

Questions to ask your doctor – Ocular Melanoma
Melanoma.org

Good news for melanoma patients here in Ireland
New clinical trial announced for patients with Malignant Melanoma

Cork Cancer Research Centre (CCRC), which is based at University College Cork, has announced the launch of a new clinical trial for the treatment of malignant melanoma, which aims to significantly improve outcomes for patients with this form of skin cancer.

In Ireland there are approximately 630 new cases of melanoma diagnosed each year with 110 people losing their lives to the disease annually. Melanoma mortality is increasing very rapidly with the number of deaths per annum expected to reach 150 by 2020.

The new treatment being investigated involves a combination of Ipilimumab (“Ipi”, tradename Yervoy), a Bristol-Myers Squibb (BMS) drug, and tumour Electroporation, which is pioneered at CCRC. It aims to open up cancer cells with electrical pulses to facilitate the immunotherapy treatment to be even more effective, enabling the patient’s immune system to respond against the cancer. The study is supported by UCC, BMS and Breakthrough Cancer Research.

Doctors with patients who may be suitable for this trial should refer them to Dr Power of the Oncology Clinical Trials Unit in Cork University Hospital or Dr Declan Soden of the Cork Cancer Research Centre in University College Cork. Patients can contact Dr Power through his PA at 021 492 2893.

Read more
breakthroughcancerreasearch.ie

Just diagnosed with melanoma?

If you’re reading this, you or someone you know has undergone a biopsy or other tests in which the diagnosis of melanoma has been confirmed. First, know that you are not alone. Second, arm yourself with information and resources.

Understanding Your Melanoma Diagnosis

Knowing and understanding your melaoma diagnosis is of the utmost importance, as it helps determine your treatment plan. Learn more about each stage by following the link below.

Melanoma.org

Layout 1

http://www.hse.ie



melanomaireland  is a service to the public and Web site owners. melanomaireland is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use, reference to, or reliance on any information contained within the site. While the information contained within the site is periodically updated, no guarantee is given that the information provided in this Web site is complete, and up-to-date .Although melanomaireland  may include links providing direct access to other Internet resources, including Web sites, melanomaireland is not responsible for the accuracy or content of information contained in these sites.

 

17634total visits.